Persistence of disease after salvage therapy among relapsed or refractory Hodgkin lymphoma (HL) patients predicts poor outcome. Here, we report on 41 HL patients with active disease after salvage therapy and who received high-dose melphalan (HD-PAM) and auto-SCT as a bridge to a second autologous or an allogeneic transplantation between 2002 and 2013 at our center. Disease response was based on 18-fluoro-deoxyglucose-positron emission tomography results in all patients. Overall response rate after HD-PAM was 78% and it did not differ among PR or stable/progressive disease patients (P = 1.00). Response was associated with better OS: hazard ratio = 0.32 (95% confidence interval: 0.13-0.77, P = 0.01) irrespective of disease status before HD-PAM. Thirtythree patients (80%) were able to complete the planned treatment, intended as tandem autologous or auto-allo transplant. Hematological and extrahematological toxicity of HD-PAM was manageable, without any treatment-related death. In conclusion, HD-PAM is a valuable therapeutic option in relapsed/refractory HL patients with active disease after salvage therapy, with an impressive 78% overall response rate and 80% rate of proceeding to further transplantation. The present data may be integrated with the growing literature on new drugs in the field of relapsed/refractory HL. 
INTRODUCTION
High-dose chemotherapy (HDC) and autologous PBSC support is the gold standard for relapsing or refractory lymphoma patients. 1, 2 During the past years, several prognostic factors have been identified, and disease status before HDC is considered the strongest factor predicting the outcome of lymphoma patients. Unfortunately,~40% of them are unresponsive to salvage therapy and undergo HDC+PBSC when in progression of their disease or cannot undergo transplantation at all. 3 Treatment of these patients is difficult, as most conventional salvage regimens are ineffective and this is particularly true for those patients with unresponsive disease after first-line chemotherapy. 4 In the FDG-PET (18-fluoro-deoxyglucose-positron emission tomography) era, Moskowitz et al. 5 showed that among unresponsive Hodgkin lymphoma (HL) patients after the ifosfamide, carboplatin and etoposide (ICE) regimen, more than 50% were rescued with a gemcitabine-based second salvage chemotherapy. 5 Recently, growing data on new drugs in this setting are being published with response rates of 57-78% after failure of previous treatments. [6] [7] [8] [9] [10] However, prognosis of HL patients who do not undergo transplantation remains poor; indeed, the importance of an effective salvage therapy mainly resides in the ability to bridge refractory patients to auto-or even allo-SCT when in response of their disease. 11, 12 Our group previously reported an overall response rate (ORR) of 81% after high-dose melphalan (HD-PAM), followed by autologous stem cell infusion in 42 lymphoma patients; in that study the response to treatment was evaluated by computed tomography. 13 Those encouraging findings allowed us to continue using the same regimen even after the advent of FDG-PET for the evaluation of response. 14 The aim of the present analysis is to report the activity of HD-PAM administered as a bridge to transplant in 41 patients affected by refractory HL in the FDG-PET era, and analyzing and discussing the ability of this regimen to allow proceeding towards the established therapeutic program (auto-or allotransplant). In addition, any potential association of FDG-PET status before HD-PAM (CR vs PR vs stable (SD) or progressive disease (PD)) with final outcome will be analyzed, together with the conversion rate of response using such a regimen in this setting.
PATIENTS AND METHODS
From 2002, 137 patients affected by lymphoproliferative disease received HD-PAM followed by autologous stem cell support in any timepoint of their therapeutic history. Patients were selected from the internal transplantation database using the following items: diagnosis of HL, relapsed or refractory disease, FDG-PET response evaluation and declared transplant program by reviewing medical records for each patients: double HDC or tandem auto-allo-SCT. Then, patients were selected according to disease status before HD-PAM, excluding those in CR after salvage therapy. Only patients in PR, SD or PD after salvage regimen were included in the present analysis. Patients received HD-PAM between December 2002 and December 2013.
For each patient, the therapeutic program was established according to both disease status before HD-PAM (PR vs SD/PD) and the availability of a potential suitable allogeneic donor; indeed, HD-PAM was administered as a bridge to double HDC or tandem auto-allo-SCT. It has to be noted that: (a) local guidelines changed overtime toward a wider use of haploidentical donor for allogeneic transplantation in the past years, especially since 2009; (b) patients' clinical conditions and/or comorbidities may have guided clinicians in the preferred therapeutic choice.
Salvage chemotherapy
Most of relapsed/refractory patients included in the analysis were treated with IGEV regimen, unless contraindicated: vinorelbine (20 mg/m 2 , days 1 and 4), gemcitabine (800 mg/m 2 on days 1 and 4) and ifosfamide (2 g/m 2 , days 1-4) (IGEV). 15 The number of cycles ranged between two and four. Five patients received other salvage treatments. Previous treatments were recorded.
Autologous stem cell harvest and HDC Stem cell harvest was attempted in all patients during the first salvage chemotherapy associated with G-CSF at a dose of 5 μg/kg starting on day +7 after salvage chemotherapy. The minimum number of stem cells required to proceed to HDC was 2 × 10 6 /kg. All patients received HD-PAM (200 mg/m 2 ), administered via a central vein catheter, in 1 h infusion, with hyperhydration. Peripheral stem cells were infused the day after, defined as day 0. For patients receiving double HDC, the second course consisted of BEAM protocol, unless contraindicated.
Allo-SCT
The main allo-SCT characteristics are depicted in Table 1 . In the past (since 2009), most patients without HLA-identical donors received allo-SCT from a haploidentical family donor, using post-transplant Cy (PT-Cy). GVHD prophylaxis was different and related to donor type. Stem cell source was both BM (in haploidentical transplantation) and PBSC. Nonhaploidentical donors were mobilized by the s.c. administration of G-CSF for 5 to 6 days at 10 μg/kg per day. The target was a minimum of 4 × 10 6 CD34+/kg of recipient. All but one haploidentical donor underwent BM harvest under general anesthesia, and the target dose was 4 × 10 8 nuclear cells per kg of recipient weight. One haploidentical donor was mobilized with G-CSF.
Acute GVHD was graded according to the Keystone criteria 16 and chronic GVHD was graded retrospectively following the NIH criteria. 17 Disease evaluation by FDG-PET Disease evaluation by FDG-PET was performed before and after HD-PAM. PET images were acquired 60 min after i.v. injection of 250-450 MBq of 18 F-FDG, depending on the patient's weight. All patients fasted for at least 6 h before FDG injection. Images were acquired on a two Siemens ECAT Accel scanner (Siemens Medical Systems, Erlangen, Germany) equipped with LSO crystals. The images were interpreted by an experienced nuclear medicine physician on a Siemens Syngo Workstation (Siemens Medical Systems), using the revised criteria described by Cheson et al. 14 
Statistical methods
The χ 2 test, the Fisher's exact test and the Wilcoxon's t-test were used to evaluate the association between the clinicopathologic features and response. Factors associated with the risk of death were tested. KaplanMeier survival curves were estimated and the log-rank test was used to assess survival differences. The univariate Cox proportional hazards Abbreviations: ATG = antithymocyte globulin; MMF = mycophenolate mofetil; NMAC = nonmyeloablative conditioning regimens; PT-Cy = posttransplant Cy; RIC = reduced-intensity conditioning regimens; UD = unrelated donors. 
RESULTS
The main characteristics of the 41 patients are reported in Table 2 . Nineteen patients (46%) were in PR before HD-PAM; all patients received ABVD as first-line therapy, 36 patients (88%) received a median of four cycles (range 2-4) of IGEV, whereas five patients received therapy as follows: Stanford V (n = 1), cytarabine-based CT (n = 2), BEACOPP (n = 2); 14 patients (34%) received radiotherapy before HD-PAM. At the time of HD-PAM, 13 (32%) and 28 patients (68%) were planned to receive double HDC program and tandem auto-allo-SCT, respectively. The median time between HD-PAM and FDG-PET evaluation of response was 34 days (range 14-161). The time planned to perform the second transplant was between 45 and 60 days. The actual median time was 61 days (range 39-370).
Response to HD-PAM and ability to bridge to transplant ORR after HD-PAM was 78%: 8 (42%) and 7 (37%) out of 19 patients in PR before HD-PAM converted to CR and further PR, respectively; 17 (77%) out of 22 patients in SD/PD responded, converting into PR (n = 10) or to CR (n = 7) (Figure 1 ). ORR was not significantly different among PR and SD/PD patients (P = 1.00). A total of 33 patients (80%) completed the established program, with 11 and 22 patients undergoing a second HDC and an allo-SCT, respectively. Causes of failure among intended double HDC (i.e. patients receiving single HDC) were: medical decision according to patient's clinical status (n = 1) and disease progression early after first HDC (n = 1); failures among intended tandem auto-allo-SCT were due to: lack of suitable donor (n = 3), patient's refusal (n = 2) and death before allo (n = 1). Of these six patients experiencing failures, two received single HDC and four patients underwent double HDC (Figure 1 ). The conditioning regimen of second HDC was BEAM in 11 patients and EAM (i.e. BEAM without BCNU) in the other 4 patients. Allo-SCT was performed using a sibling HLA-identical, matched-unrelated or haploidentical donor in 6, 3 and 13 patients, respectively. Response to HD-PAM was not significantly associated with the administration of the planned treatment (P = 0.67), as 81% of responders (26/32) underwent double HDC (n = 7) or allo-SCT (n = 19) vs 67% of non-responders (6/9): n = 4 and n = 2 for double HDC and allo-SCT one, respectively.
HD-PAM and outcome
Response to HD-PAM conferred a better OS: the HR for responders vs non-responders was 0.32 (95% CI: 0.13-0.77, P = 0.01); disease status before HD-PAM was not significantly associated with OS ( Figure 2a ) and, when introduced as a covariate together with response to HD-PAM, did not change the final HR (0.33, 95% CI: 0.13-0.83, P = 0.02). At a median follow-up of 56 months, 5-year OS was 52% and 37% for PR and SD/PD patients, respectively (P = 0.40). The 5-year OS for patients obtaining a negative FDG-PET compared with persistent positive study was 75% vs 38% (P = 0.08). Patients' age, gender, staging at diagnosis, time from diagnosis to first relapse or PD were not significantly associated with OS (data not shown). A landmark analysis was performed to evaluate the impact of response to OS. The survival was calculated starting from 4.5 months after transplantation (Figure 2b) Figure 1 . Disease status before and after HD-PAM and type of treatment administered. *, Death due to PD before the 2nd HDC; #, one patient (pt) received a 2nd HDC owing to the lack of a suitable allogeneic donor; ø, pts refusal of allo-SCT; $, medical decision according to pts clinical status; £, death due to infection before allo-SCT.
(double HDC auto-vs auto-allo-SCT): the 5-year PFS and OS were 29% vs 36% (P = 0.6) and 35% vs 53% (P = 0.2), respectively. In the auto-allo-SCT group, the survival was not different comparing the donor type (HLA-identical vs haploidentical donor): the 5-year PFS and OS were 38% vs 39% (P = 0.8) and 56% vs 61% (P = 0.6), respectively. At last follow-up, 14 patients (34%) died of lymphoma progression and five (12%) of non-relapse mortality, all after allo-SCT. Causes of non-relapse mortality were: bacterial pneumonia (n = 2), septic shock (n = 1), multiorgan failure (n = 1) and acute GVHD (n = 1). The relapse (or PD) rate from HD-PAM was 56% (23 out of 41 patients). Median PFS of patients who responded to HD-PAM was 10 months.
Hematological and extrahematological toxicity After a median PBSC infused of 5.0 × 10 6 CD34+/kg (range 2.2-15.5), all patients engrafted with a median neutrophil take of 12 days (range: 6-41); median duration of hospitalization was 18 days (range: 13-56). Incidence of grade 3-4 mucositis was 54% (22 out of 41 patients); median number of platelet units transfused was 1 (range: 0-47) and of RBCs was 2 (range: 0-31). Other severe (i.e. National Cancer Institute-Common Terminology Criteria grade 3-4) extrahematological toxicities included pneumonia (n = 4), diarrhea (n = 2) and BK virus-associated cystitis (n = 1) and candidemia (n = 1). Fever of undetermined origin occurred in 21 patients, alone (n = 13) or associated with non-microbiologically documented diarrhea (n = 8).
DISCUSSION
The present study suggests that HD-PAM is effective as rescue therapy in patients with refractory HL and allows to proceed to the planned treatment in 80% of them, with the achievement of disease response after HD-PAM in 78% of cases. At our Institution, tandem HDC or tandem auto-allo-SCT are preferred therapeutic options in lymphoma patients not reaching CR after salvage chemotherapy, based on the poor outcome reported with the use of single HDC; [18] [19] [20] indeed, disease status before transplantation is a well-known, independent prognostic factor in lymphoma patients. 18, [21] [22] [23] From present results it emerges that HD-PAM as a bridge therapy may be a challenging option in this setting of poor-prognosis patients. Interestingly, in our hands HD-PAM converted 77% of refractory patients (17 out of 22 patient in SD or PD before HD-PAM) into PR, or even CR (Figure 1) , thus enabling them to proceed to further therapy. Importantly, here response to HD-PAM was independently associated with better OS, whereas disease status before HD-PAM did not; the survival advantage was due to the ability of an HD-PAM to achieve significant tumor shrinkage even in patients with SD or PD. As expected, nonresponding patients had a poor outcome even in the presence of a second transplantation, thus indicating that much effort is still needed for these patients. Although non-negligible, both hematological and extrahematological toxicities after HD-PAM appeared to be manageable and no treatment-related mortality was observed in this series.
Some previous reports showed the feasibility of such a tandem approach, with encouraging results in both HL and NHL. 12, [24] [25] [26] In the setting of double HDC, a prospective study from the former GELA/SFGM group showed that, in the higher-risk group of patients (refractory and with more than two adverse prognostic factors), this approach of the 5-year freedom from second failure and OS was 41% and 52%, respectively, with the better results in those with chemosensitive disease to salvage therapy. 27 In a pilot study adopting the double HDC approach, Fung et al. 28 reported that, in refractory or poor-prognosis patients, the 5-year OS, PFS and freedom from progression were 54%, 49% and 55%, respectively. In a retrospective study, the double HDC approach was more effective in patients achieving FDG-PET-defined PR, than single HDC (5-year PFS 43% vs 0%). 21 Actually some limitations exist, mainly due to inability of a proportion of patients to collect an adequate amount of autologous stem cells and to the lack of availability of a suitable allogeneic donor in some instances; however, with the growing use of new mobilizing drugs such as plerixafor 29 and of unmanipulated haploidentical grafts, an allogeneic donor may be virtually available for all patients, 30 thus improving the feasibility of an allogeneic procedure in those patients lacking an HLA-identical donor. As a retrospective analysis, the present study suffers from a potential selection bias of patients; in fact, we acknowledge that poor mobilizers or patients with early progressive disease may have been excluded because of the lack of adequate collection of PBSC, preventing them to proceed to HD-PAM; however, although difficult to evaluate, the number of poor mobilizers is expected to be low in this population of mainly younger, not heavily pretreated patients. In addition, as the autologous stem cells were collected at the end of the second cycle of salvage regimen for most patients, adequate collection occurred even in early progressive diseases (see Figure 1) .
Our results have to be interpreted and integrated in the present panorama of refractory HL: new emerging drugs in the field such as brentuximab vedotin (BV) and bendamustine showed an ORR of 75% (34% CR rate) and 53% (33% CR rate), 6, 31 High-dose melphalan as a bridge to transplant in HL patients L Castagna et al recent phase II study on 129 patients 10 found tumor reductions in 74% of patients, with 27% ORR after panobinostat monotherapy.
However, considering BV as the most active and suitable drug for refractory patients, it is evident that the probability of performing allo-SCT or HDC is surprisingly low. In the phase II trial, including only patients (n = 102) relapsing or progressing after HDC, only 8 patients proceeded to allograft, although the responding and potentially candidate patients were 76. 6 In the English study, 7 22 out of 24 patients treated with BV (HL plus NHL) were potentially candidate to allo-SCT, but because of progression, only 4/22 received transplantation. In the Italian study, 32 14 patients achieved a CR (out of 65), and four received allo-SCT and three HDC. However, most of the patients progressed before receiving allo-SCT or auto-SCT (final ORR 29%). In the German study, 33 no patients underwent allo-SCT. Finally, in a study 34 addressing the question of BV as bridge to allo-SCT, 18 (out of 36 candidate) did not receive allograft, mainly because of patient preference (n = 18) or progressive disease (n = 7). Overall, these data suggest that few patients responding to BV proceed to allograft or to HDC when indicated. It seems that progression of disease is the most relevant reason, suggesting that the response obtained is ephemeral. However, it should be noted that in our study, we are strongly committed to perform allo-SCT or HDC, which can influence the high performance of second transplant. Finally, the OS obtained with the sequence reported in the present study compared well with that updated recently by Chen et al. 35 However, this comparison should be taken with caution. In conclusion, HD-PAM followed by autologous PBSC is a valuable therapeutic option in relapsed/refractory HL patients with active disease after salvage therapy, with an impressive 78% ORR and 80% rate of proceeding to further transplantation (auto-or allo-SCT). The present data may be integrated with the growing literature on new drugs in the field. However, much effort is needed for those non-responding patients whose prognosis remains poor.
